Nike announced that David Denton, currently a senior finance officer at Pfizer, will become chief financial officer on August 17. He will replace Matthew Friend, who remains through Sept. 4 to aid the handoff. CEO Elliott Hill praised Denton as a “proven public‑company CFO” capable of steering consumer brands with discipline and strategic investment.

The change follows a board review and signals tighter oversight. Quarters showed revenue declines in its crucial China market and lingering weakness across Europe, the Middle East and Africa. The company expects to leverage Denton’s expertise in treasury management to optimize cash flows, a move aimed at tightening cost controls and restoring analyst confidence.

Investors will gauge Denton’s impact on Nike’s balance sheet before earnings. A CFO with a pharma background may bring stricter capital allocation and risk management, potentially narrowing the widening margin gap with rivals. The transition, finalized before year‑end, sets a deadline for the finance team to deliver improvements.